2024
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: e240002. PMID: 38244274, DOI: 10.6004/jnccn.2024.0002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLocally advanced diseaseMerkel cell carcinomaAdvanced diseaseLocally advanced Merkel cell carcinomaAdvanced Merkel cell carcinomaNode negative statusSystemic therapy optionsIn-transit diseaseNCCN Guidelines InsightsCell carcinomaNCCN GuidelinesClinical stageDiagnostic workupTherapy optionsTreatment optionsNegative statusInstitutional reviewNCCNDiseaseGuidelinesOptionsCarcinomaWorkupPatientsPanel members
2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 1181-1203. PMID: 37935106, DOI: 10.6004/jnccn.2023.0056.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBasal cell carcinomaNCCN Clinical Practice GuidelinesClinical practice guidelinesSkin cancerTreatment optionsPractice guidelinesBasal cell skin cancerPrevalent treatment optionPrevious medical therapyLimitation of functionBCC occurrenceMedical therapyRisk stratificationBCC developmentCell carcinomaCancerCommon formOncologyAnnual rateEstimated ratesGuidelinesKey playersSurgeryCarcinomaHigh frequencyCase report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases
Rusheen J, Clune J, Ariyan S, Baumann R, Kluger H, Olino K, Weiss S. Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases. Frontiers In Oncology 2023, 13: 1217816. PMID: 37476373, PMCID: PMC10354444, DOI: 10.3389/fonc.2023.1217816.Peer-Reviewed Case Reports and Technical NotesMerkel cell carcinomaDuration of surveillanceLate recurrenceCell carcinomaMetastatic Merkel cell carcinomaPrimary Merkel cell carcinomaMetastases 15 monthsSuch late recurrencesPredictors of recurrenceNodal recurrenceDefinitive therapyFirst recurrenceDisease resectionNodal metastasisPhysical examinationRare tumorPrimary diagnosisPrimary tumorRisk factorsHigh riskNational guidelinesRecurrenceOptimal durationPatientsCarcinomaEvaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability
Belzer A, Pach J, Mortlock R, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal J. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD International 2023, 11: 174-175. PMID: 37252181, PMCID: PMC10213716, DOI: 10.1016/j.jdin.2023.02.007.Peer-Reviewed Original Research
2021
Squamous cell carcinoma arising in long-standing necrobiosis lipoidica treated with radical resection and split-thickness skin graft
Xie CB, Ring N, Damsky W, McNiff JM, Olino K, Odell I. Squamous cell carcinoma arising in long-standing necrobiosis lipoidica treated with radical resection and split-thickness skin graft. JAAD Case Reports 2021, 19: 90-93. PMID: 35024397, PMCID: PMC8724883, DOI: 10.1016/j.jdcr.2021.11.005.Peer-Reviewed Case Reports and Technical NotesASO Author Reflections: The Utility of Overall Survival as an Outcome in the Study of Merkel Cell Carcinoma
Esposito AC, Jacobs D, Olino K. ASO Author Reflections: The Utility of Overall Survival as an Outcome in the Study of Merkel Cell Carcinoma. Annals Of Surgical Oncology 2021, 29: 425-426. PMID: 34523003, DOI: 10.1245/s10434-021-10791-8.Commentaries, Editorials and LettersAssessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States. JAMA Dermatology 2021, 157: 59-65. PMID: 33146688, PMCID: PMC7643047, DOI: 10.1001/jamadermatol.2020.4102.Peer-Reviewed Original ResearchConceptsMerkel cell carcinomaBirth cohort effectsCell carcinomaIncidence rateCalendar periodBirth cohortPatient ageNew casesCohort effectsEnd Results Program databaseCross-sectional retrospective studyLongitudinal cohort studyHigh incidence rateAge-adjusted ratesRisk factor exposureRecent birth cohortsCohort studyCarcinoma incidenceRetrospective studyNeuroendocrine cancerAge effectsProgram databaseCohort analysisMAIN OUTCOMECarcinoma
2020
Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementNeoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical NotesAssessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Park H, Young M, Olino K, Rahmati R, Mehra S, Burtness B, Judson B. Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1191-1192. DOI: 10.1016/j.ijrobp.2019.11.099.Peer-Reviewed Original Research